Expedia Group Inc vs Neurocrine Biosciences Inc — how do they compare? Expedia Group Inc trades at $321.16 (market cap $37.69B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Expedia Group Inc is far larger — about 2.2× Neurocrine Biosciences Inc's market cap, and Expedia Group Inc pays a 0.61% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| EXPE | NBIX | |
|---|---|---|
Market Cap | $37.69B | $16.76B |
Sector | Consumer Cyclical | Health |
52-Week High | $321.07 | $185.50 |
52-Week Low | $188.51 | $123.10 |
Enterprise Value | $36.25B | $16.78B |
Dividend Yield | 0.61% | — |
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $310.68, up 1.34% on the day, with a bullish technical signal supported by moving averages and strong quarterly earnings beats. The company reported Q2 2026 EPS of $5.76, exceeding expectations, driven by 14% revenue growth and robust B2B performance. Valuation metrics include a P/E of 19.54 and P/S of 2.51, with net income margin improving to 12.97% in 2025. Recent news highlights AI integration and raised full-year guidance, reflecting operational strength.
The outlook for EXPE is positive, with earnings momentum and strategic expansions offering upside potential, though high debt levels and travel industry volatility pose risks. Analysts project a consensus price target of $322.95, with 47% buy ratings, indicating cautious optimism. Investors should weigh solid fundamentals against macroeconomic sensitivities affecting travel demand.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Trailing returns across standard periods
Latest headlines on both assets
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →